title: Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice.
abstract: It is well established that the dopamine (DA) and serotonin (5-HT) systems have extensive and complex interactions. However, the effects of specific 5-HT receptor agonists on traditionally DA-related behaviors remain unclear. Our goal in these studies was to characterize the effects of 5-HT receptor agonists on measures of locomotor activity and vertical rearing. The SSRIs fluoxetine and citalopram produced significant decreases in locomotor activity and vertical rearing at the highest doses used with females significantly more sensitive to citalopram. The 5-HT(1A) agonist 8-OH-DPAT and the 5-HT(2C) agonist MK 212 significantly decreased activity in both male and female mice, with females more sensitive to 8-OH-DPAT. In contrast, the 5-HT(1B) agonist RU 24969 and the 5-HT(2A) agonist DOI both increased activity, with DOI exhibiting differential effects with regard to sex. Finally, the 5-HT(3) agonist SR 57227 produced significant locomotor increases only in female mice at the lowest dose. The results of these experiments define locomotor profiles of several 5-HT agonists in male and female C57BL/6J mice, providing a foundation for further explorations of 5-HT receptor effects on activity.
authors.affiliation: Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
authors.forename: Bethany R
authors.initials: BR
authors.lastname: Brookshire
authors.forename: Sara R
authors.initials: SR
authors.lastname: Jones
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D019540:Area Under Curve; D001522:Behavior, Animal / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006185:Habituation, Psychophysiologic; D007274:Injections, Intraperitoneal; D008297:Male; D016555:Matched-Pair Analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D020033:Protein Isoforms / Q000378:metabolism; D011897:Random Allocation; D011985:Receptors, Serotonin / Q000378:metabolism*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D012727:Sex Characteristics; D013997:Time Factors
chemical_list: D020033:Protein Isoforms; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists
references.citation: Brain Res. 1975 Dec 12;100(1):163-9
references.pmid: 1237342
references.citation: Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):325-32
references.pmid: 11812540
references.citation: Pharmacol Biochem Behav. 2002 Jul;72(4):857-63
references.pmid: 12062575
references.citation: J Pharmacol Exp Ther. 1965 Jan;147:96-102
references.pmid: 14255167
references.citation: Beijing Da Xue Xue Bao Yi Xue Ban. 2003 Feb 18;35(1):54-60
references.pmid: 12920810
references.citation: Neurosci Lett. 2000 Mar 3;281(1):9-12
references.pmid: 10686403
references.citation: Neuropharmacology. 2005 Dec;49(8):1210-9
references.pmid: 16165167
references.citation: J Neurochem. 2006 Dec;99(5):1363-76
references.pmid: 17074068
references.citation: Pharmacol Ther. 2007 Feb;113(2):296-320
references.pmid: 17049611
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1321-30
references.pmid: 15085085
references.citation: Psychopharmacology (Berl). 2005 Dec;183(2):257-64
references.pmid: 16220334
references.citation: J Neurochem. 2006 Nov;99(3):976-88
references.pmid: 16942594
references.citation: Brain Res. 1982 Dec 16;253(1-2):231-41
references.pmid: 6891283
references.citation: Alcohol. 1996 Nov-Dec;13(6):569-74
references.pmid: 8949951
references.citation: Pharmacol Biochem Behav. 2002 Apr;71(4):667-80
references.pmid: 11888558
references.citation: Neuroscience. 1999;94(1):251-9
references.pmid: 10613515
references.citation: Neuropsychopharmacology. 2006 Nov;31(11):2332-40
references.pmid: 16855535
references.citation: Eur J Pharmacol. 1991 Dec 17;209(3):151-6
references.pmid: 1797560
references.citation: J Neurochem. 2001 Nov;79(3):626-35
references.pmid: 11701766
references.citation: Psychopharmacology (Berl). 1999 Jan;141(3):326-31
references.pmid: 10027515
references.citation: Am J Psychiatry. 2003 Sep;160(9):1643-50
references.pmid: 12944340
references.citation: Behav Brain Res. 2006 Feb 28;167(2):328-41
references.pmid: 16256213
references.citation: J Neurophysiol. 2005 Nov;94(5):3397-405
references.pmid: 16049141
references.citation: J Pharmacol Exp Ther. 2004 Nov;311(2):711-9
references.pmid: 15226384
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):372-7
references.pmid: 14691264
references.citation: Ann N Y Acad Sci. 1998 Jun 30;851:357-63
references.pmid: 9668626
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2036-40
references.pmid: 9050900
references.citation: Brain Res. 1987 Dec 1;435(1-2):71-83
references.pmid: 2892580
references.citation: Neuropsychopharmacology. 2008 Feb;33(3):619-26
references.pmid: 17487226
references.citation: Br J Pharmacol. 1996 Feb;117(4):657-66
references.pmid: 8646411
references.citation: Neuroscience. 2002;113(4):939-55
references.pmid: 12182899
references.citation: Life Sci. 1995 Nov 17;57(26):2455-66
references.pmid: 8847967
references.citation: Behav Brain Res. 1996;73(1-2):31-5
references.pmid: 8788473
references.citation: J Pharmacol Exp Ther. 1998 Aug;286(2):913-24
references.pmid: 9694950
references.citation: J Neural Transm (Vienna). 1996;103(1-2):131-46
references.pmid: 9026367
references.citation: J Chromatogr B Biomed Sci Appl. 1997 Dec 19;704(1-2):259-63
references.pmid: 9518159
references.citation: Synapse. 2006 Feb;59(2):74-81
references.pmid: 16270301
references.citation: Eur J Pharmacol. 2001 Jun 22;422(1-3):91-9
references.pmid: 11430919
references.citation: Behav Pharmacol. 2007 Dec;18(8):791-800
references.pmid: 17989517
references.citation: Behav Brain Res. 1988 Sep 1;30(1):55-68
references.pmid: 2458741
references.citation: AAPS J. 2007 Jan 05;9(1):E1-10
references.pmid: 17408232
references.citation: Science. 1974 Sep 20;185(4156):1067-9
references.pmid: 4212011
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):379-83
references.pmid: 8878071
references.citation: Pharmacol Biochem Behav. 1996 Mar;53(3):535-9
references.pmid: 8866952
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1246-54
references.pmid: 15131246
references.citation: Neuropharmacology. 2003 Mar;44(3):342-53
references.pmid: 12604093
references.citation: Drug Metab Dispos. 1998 Jan;26(1):20-4
references.pmid: 9443847
references.citation: Eur J Pharmacol. 1982 Nov 19;85(2):125-32
references.pmid: 7151866
references.citation: Psychopharmacology (Berl). 1992;106(4):531-9
references.pmid: 1533722
references.citation: Pol J Pharmacol Pharm. 1992 Mar-Apr;44(2):135-46
references.pmid: 1357637
references.citation: J Med Chem. 1981 Aug;24(8):921-3
references.pmid: 6460101
references.citation: Brain Res. 1994 Aug 22;654(2):324-30
references.pmid: 7987681
references.citation: Br J Pharmacol. 1971 Aug;42(4):643P-645P
references.pmid: 5116046